Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(03): 277-280
DOI: 10.4103/wjnm.WJNM_65_19
Case Report

Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease

Benjamin Froitzheim
1   University of Regensburg, Regensburg, Germany
2   Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
,
Raef Boktor
2   Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
,
Eddie Lau
2   Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
3   Department of Radiology, Austin Health, Heidelberg, Victoria
4   Department of Medicine, University of Melbourne, Melbourne
,
Sze Lee
2   Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
5   Olivia Newton-John Cancer Research Institute, Austin Health
6   School of Cancer Medicine, LaTrobe University, Melbourne, Australia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This case report presents a patient with recurrent pleomorphic mantle cell lymphoma (MCL), which is a relatively rare but aggressive type of lymphoma. A positron emission tomography/computed tomography scan performed to assess treatment response demonstrated a complete metabolic response in the sites of primary disease while also revealing new subcutaneous lesions, which were biopsy-proven recurrent disease. This case illustrates the importance of the different biological behavior of MCL, whereby new sites of metabolically active lesions can represent recurrent disease, even though there is a complete metabolic response at sites of primary disease.

Keywords

Fluorodeoxyglucose-positron emission tomography/computed tomography - mantle cell lymphoma - recurrent lymphoma - treatment response

Financial support and sponsorship

Nil.




Publication History

Received: 05 September 2019

Accepted: 10 October 2019

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
  • 2 A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997;89:3909-18.
  • 3 Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
  • 4 Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
  • 5 Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci 2019;20:4417.
  • 6 Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med 2011;25:701-16.
  • 7 Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23.
  • 8 Bailly C, Carlier T, Touzeau C, Arlicot N, Kraeber-Bodéré F, Le Gouill S, et al. Interest of FDG-PET in the management of mantle cell lymphoma. Front Med (Lausanne) 2019;6:70.
  • 9 Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009;50:1257-60.
  • 10 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32:3059-68.
  • 11 Metser U, Tau N. Benign cutaneous and subcutaneous lesions on FDG-PET/CT. Semin Nucl Med 2017;47:352-61.